Seeking Alpha

Pozen (POZN) resumes trading -18.1% AH after the FDA said the company's Phase 1 study failed to...

Pozen (POZN) resumes trading -18.1% AH after the FDA said the company's Phase 1 study failed to demonstrate the bioequivalence of PA32540 to enteric-coated aspirin 325 mg using acetylsalicylic acid as the analyte, and further study will be needed.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector